We determined the serum levels of soluble CD40 ligand (sCD40L) in patients with chronic coronary artery disease (CAD) and acute coronary syndrome (ACS). Patients with unstable angina (UA) and myocardial infarction (MI) showed significantly higher levels (P < .001) of sCD40L compared with patients with stable angina (SA) and controls; particularly, high levels occurred in patients with UA (UA: 9.23 ± 2.92, MI: 7.38 ± 1.05, SA: 4.42 ± 1.08; control: 4.01 ± 0.87 ng/mL). There was no significant difference in sCD40L levels between patients with UA and MI or between patients with SA and controls. Levels of sCD40L did not show any significant correlation with peak creatine kinase (CK), CK-MB isoenzyme activity in patients with MI, troponin T serum levels in patients with UA or with culprit vessel (CV) complexity score (CVCS), type of CV lesion, or vessel score in patients with UA or MI. These results suggest that CD40L plays a pathogenic role in triggering ACS.
Fuster V., Badimon L., Badimon JJ, et al. The pathogenesis of coronary artery disease in the acute coronary syndromes. N Engl J Med. 1992;326(4):242-250.
2.
Ross R.The pathogenesis of atherosclerosis. A perspective for the 1990s. Nature. 1993;362(6423):80-89.
3.
Athyros VG, Kakafika AI, Karagiannis A., et al. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis. 2008;200(1):1-12.
4.
Biasucci LM, Vitelli A., Liuzzo G., et al. Elevated levels of interleukin-6 in unstable angina. Circulation. 1996;94(5): 874-877.
5.
Moreno PR, Falk E., Palacios IF, et al. Macrophage infiltration in acute coronary syndromes: implications of plaque rupture. Circulation. 1994;90(2):775-778.
6.
Dollery CM, Mcewan JR, Henney A.Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77(5):863-868.
7.
Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques . J Clin Invest. 1994;94(6):2493-2503.
8.
Serneri GG, Abbate R., Gori AM, et al. Transient intermittent lymphocyte activation is responsible for the instability of angina. Circulation. 1992;86(3):790-797.
9.
Gregory SA, Edgington TSTissue factor induction in human monocytes: two distinct mechanisms displayed by and different alloantigen responsive T cell clones. J Clin Invest. 1985;76(6): 2440-2445.
10.
Foy TM, Arufro A., Bojorath J., et al. Immune regulation by CD40 and its ligand GP30. Annu Rev Immunol.1996;14:591-617. Review.
11.
Mach F., Schönbeck U., Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997;94(5):1931-1936.
12.
Hollenbaug D., Grosmaire RS, Kullas CD, et al. The human T cell antigen gp 39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J. 1992;11(12):4313-4321.
Henn V., Slupsky JS, Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998 ;351(6667):591-594.
15.
Mach F., Schonberck U., Bonnefoy JY, et al. Activation of monocytes/ macrophage functions related to acute atheroma complication by ligation of CD40.Induction of collagenase, stromelysin and tissue factor. Circulation. 1997;96(2):396-399.
16.
Braunwald E.Unstable angina. A classification. Circulation. 1989;80(2):410-414.
17.
Tunstall-Pedoe H., Kuulasmaa K., Amouyel P., et al. Myocardial infarction and coronary deaths in the World Health Organisation MONICA project . Circulation.1994;90(1):583-612.
18.
Ahmed WH, Bittl JH, Braunwald E.Relation between clinical presentation and angiographic findings in unstable angina pectoris, and comparison with that in stable angina. Am J Cardiol. 1993;72(7):544-550.
19.
Bakker AJ, Koelemay MJ, van Vlies B., et al. Exclusion of acute myocardial infarction. The value of measuring creatine kinase slope. Eur J Clin Chem Clin Biochem. 1995;33(6):351-363.
20.
Ambrose JA, Winters SL, Stern A., et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol. 1985;5(3):609-616.
21.
Ambrose JA, Israel DHAngiography in unstable angina. Am J Cardiol. 1991;68(7):78B-84B.
22.
Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology /American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (subcommittee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol. 1988; 12(2):529-545.
23.
Kusuoka H., Hoffman JIE.Advice on statistical analysis for Circulation Research. Circ Res. 2002;91(8):662-671.
24.
Liuzzo G., Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med. 1994;331(7):417-424.
25.
De Beer FC, Hind CRK, Fox KM, et al. Measurement of serum C-reactive protein concentration in myocardial ischemia and infarction . Br Heart J. 1982;47(3):239-243.
26.
Berk BC, Weintraub WS, Alexander RWElevation of C-reactive protein in ‘active’ coronary artery disease . Am J Cardiol. 1990; 65(3):168-172.
27.
Silva AR, Pacheco P., Vieira-de-Abreu A., et al. Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon. Biochim Biophys Acta. 2009;1791(11):1066-1075.
28.
Takano T., Itabe H., Mori M., et al. Molecular pathology in atherosclerosis: the mechanism by which cholesteryl ester accumulates in atheromatous aorta. Yakugaku Zasshi. 2008;128(10): 1383-1401.
29.
Moreno PR, Fallon JTInflammation in acute coronary syndromes. In: Schulthesis H, Schwimmbeck P, eds. The Role of Immune Mechanisms in Cardiovascular Disease. Berlin: Springer;1997:213-229.
30.
Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocytes and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100(6):614-620.
31.
Schönbeck U., Mach F., Sukhova GK, et al. Regulation of matrix metalloproteinases expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res. 1997;81(3):448-454.
32.
Zhou L., Stordeur P., De Lavareille A., et al. CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity. Thromb Haemost. 1998 ;79(5):1025-1028.
33.
Gurfinkel EP , Scircia BM, Bozovich G., et al. Serum neopterin levels and the anigraphic extent of coronary arterial narrowing in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 1999;83(4): 515-518.
34.
Auer J., Berent R., Labetanig E., et al. Serum neopterin and activity of coronary artery disease. Heart Dis. 2001;3(5):297-301.
35.
Ridker PM, Cushman M., Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 ;336(14):973-979.
36.
Tatzber F., Rabl H., Koriska E., et al. Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. 1991;89(2-3):203-208.
37.
Schumacher M., Eber B., Tatzber F., et al. Neopterin levels in patients with coronary artery disease. Atherosclerosis . 1992;94(1):87-88.
38.
García-Moll X., Coccolo F., Cole D., et al. Serum neopterin and complex stenosis morphology in patients with unstable angina. J Am Coll Cardiol.2000;35(4):956-862.
39.
Lendon CL, Daviews MJ, Born GV, et al. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis. 1991 ;87(1):87-90.
40.
Loree HM, Kamm RD, Stringfellow RG, et al. Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res. 1992;71(4):850-858.
